Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC |
| Type de publication | Journal Article |
| Year of Publication | 2014 |
| Auteurs | Touzeau C, Leux C, Bouabdallah R, Roussel M, Delarue R, Bouabdallah K, Thieblemont C, Cacheux V, Cartron G, Compain L, Gyan E, Morschhauser F, Casasnovas O, Moles M-P, Michallet A-S, Gressin R, Damaj G, Rose C, Sirvent A, Hermine O, Mohty M, Milpied N, Le Gouill S |
| Journal | ANNALS OF HEMATOLOGY |
| Volume | 93 |
| Pagination | 233-242 |
| Date Published | FEB |
| Type of Article | Article |
| ISSN | 0939-5555 |
| Mots-clés | Autologous stem cell transplantation, Mantle cell lymphoma, prognostic factors |
| Résumé | {Autologous stem cell transplantation (ASCT) is considered as an attractive treatment option for young mantle cell lymphoma (MCL) patients. This retrospective SFGM-TC study analyzed the outcome of 500 MCL patients treated with ASCT and investigated parameters that may modify the outcome of patients who proceeded to ASCT upfront (n = 396). For all patients, median age at ASCT was 56 years (range, 26-71). Median follow-up was 34 months. Three-year progression free survival (PFS) and overall survival (OS) were 63.5 % [95 % CI, 58.7-68.6 %] and 79.5 % [95 % CI, 75.3-83.4 %], respectively. Median time from ASCT to relapse was 22 months (range, 0-136 m). For patients transplanted upfront and in multivariate analysis, age (HR = 2 [1.2-3.4] |
| DOI | 10.1007/s00277-013-1860-8 |